{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Perrone E"],"funding":["NHGRI NIH HHS","National Human Genome Research Institute"],"pagination":["1761-1766"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8988015"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["182(7)"],"pubmed_abstract":["Gomez-López-Hernández syndrome (GLHS) is characterized by rhombencephalosynapsis (RES), alopecia, trigeminal anesthesia and a distinctive phenotype, including brachyturricephaly. It has been suggested that GLHS should be considered as part of the spectrum of RES-associated conditions that include alopecia, trigeminal anesthesia, and craniofacial anomalies, rather than a distinct entity. To the best of our knowledge, 57 patients with GLHS have been described. Despite its first description in 1979, the etiology of this syndrome remains unknown. Here, we describe, to our knowledge, the first case of a patient with GLHS who was molecularly evaluated and had been prenatally exposed to misoprostol. We also reviewed the clinical and morphological features of the patients described to date to better delineate the phenotype and focus on any evidence for adverse pregnancy outcomes or exposure, including teratogens."],"journal":["American journal of medical genetics. Part A"],"pubmed_title":["Gomez-Lopez-Hernandez syndrome: A case report with clinical and molecular evaluation and literature review."],"pmcid":["PMC8988015"],"funding_grant_id":["U54 HG006542","1U54HG006542"],"pubmed_authors":["D'Almeida V","Perrone E","Cernach MCSP","de Macena Sobreira NL","Burlin S","Soares MFF","de Mello CB","de Oliveira AC","Alvarez Perez AB"],"additional_accession":[]},"is_claimable":false,"name":"Gomez-Lopez-Hernandez syndrome: A case report with clinical and molecular evaluation and literature review.","description":"Gomez-López-Hernández syndrome (GLHS) is characterized by rhombencephalosynapsis (RES), alopecia, trigeminal anesthesia and a distinctive phenotype, including brachyturricephaly. It has been suggested that GLHS should be considered as part of the spectrum of RES-associated conditions that include alopecia, trigeminal anesthesia, and craniofacial anomalies, rather than a distinct entity. To the best of our knowledge, 57 patients with GLHS have been described. Despite its first description in 1979, the etiology of this syndrome remains unknown. Here, we describe, to our knowledge, the first case of a patient with GLHS who was molecularly evaluated and had been prenatally exposed to misoprostol. We also reviewed the clinical and morphological features of the patients described to date to better delineate the phenotype and focus on any evidence for adverse pregnancy outcomes or exposure, including teratogens.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-05T15:53:04.993Z","creation":"2025-04-05T15:53:04.993Z"},"accession":"S-EPMC8988015","cross_references":{"pubmed":["32302043"],"doi":["10.1002/ajmg.a.61594"]}}